Shattuck Labs Inc
NASDAQ:STTK
Shattuck Labs Inc
Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.
Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.
Clinical Progress: Shattuck Labs reported encouraging early clinical efficacy with its lead candidate SL-172154 ('154'), including the first observed responses in both hematologic and solid tumor trials.
Ovarian Cancer Data: Interim results from the Phase Ib PROC trial show a 27% overall response rate for 154 plus PLD, notably higher than the 4% benchmark for PLD alone in the JAVELIN trial.
Hematologic Data: Early activity was observed in relapsed/refractory AML and high-risk MDS, including a rapid response in a heavily pretreated TP53 mutant AML patient.
Safety Profile: 154 continues to demonstrate an acceptable safety profile, with no destructive anemia, differentiating it from other CD47 agents.
Financial Position: Shattuck ended Q3 with $101.1 million in cash and expects this to fund operations through year-end 2024.
Guidance Reiteration: Management reiterated guidance on cash runway and milestone timing, expecting key data updates and cohort completions in late 2023 and mid-2024.
